Tag: Metabolic & GLP-1
PharmaSignal — Metabolic & GLP-1 therapeutic area
Biocytogen and Sihuan partner to advance new therapeutics for weight loss
Pharmaceutical Business Review
Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation.
FDA approves Lilly obesity pill, triggering battle with Novo Nordisk
BioPharma Dive
Foundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.
Lilly bags FDA okay for Wegovy pill rival orforglipron
Pharmaphorum
Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill.
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
BioSpace
The FDA approved Eli Lilly’s orforglipron–to be known as Foundayo–on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
Ambrosia adds a megaround for obesity drugs
BioPharma Dive
The $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing.
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
BioSpace
While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.
NHS to offer Wegovy to a million more people in England
Pharmaphorum
The NHS in England will make Novo Nordisk’s Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Novo hits back at rivals with cut-price Wegovy subscriptions
Pharmaphorum
Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
BioPharma Dive
Wave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts.